No abstract

Purpose Evaluate the efficacy and safety of triple therapeutic method (Hepatic Aarterial Infusion Chemotherapy—HAIC, lenvatinib and sequential ablation) in the treatment for Advanced Hepatocellular carcinoma (Ad‐HCC). Materials and Methods From November 2018 to June 2021, data from 150 consecutive Ad‐HCC patients were collected. All patients received HAIC combined with lenvatinib (H‐L group, n = 97) or HAIC combined with lenvatinib and sequential ablation (H‐L‐A group, n = 53). Complications, overall survival (OS), progression‐free survival (PFS) and intrahepatic progression‐free survival (IPFS) were compared between both groups. Results No significant differences of baseline characteristics were found between groups. The time of median follow‐up was 17.8 months (range, 6.8, 37.6 months). In comparison to the H‐L group, the H‐L‐A group patients showed significantly longer median OS (>30 months vs 13.6 months, respectively; p = 0.010), PFS (12.8 vs. 5.6 months, respectively; p < 0.001), and IPFS (14.6 vs. 6.8 months, respectively; p = 0.002). According to the results from uni‐ and multivariable analyses, we considered α‐fetoprotein and treatment modality as two survival independent prognostic factors. No significant change of the complication incidences was observed between H‐L group and H‐L‐A group (12.4% vs. 11.3%, p = 0.890). Conclusion Compared to HAIC combined with lenvatinib only, HAIC combined with lenvatinib and sequential ablation was safer and more effective, improving survival outcomes of Ad‐HCC patients. A prospective study will be designed validate the retrospective results.

No abstract

To investigate e cacy and safety of hepatic arterial infusion chemotherapy combined with lenvatinib(HAIC-Len) and HAIC alone for the treatment of advanced hepatocellular carcinoma(Ad-HCC). MethodsTotally 349 patients with Ad-HCC participated in the research from February 2018 to October 2020. On the basis of propensity score matching(PSM), 132 and 110 cases were assigned to the HAIC group and the HAIC-Len group, respectively, with a ratio of 1:1. Progression-free survival(PFS), overall survival(OS), and complications were compared between two groups. The Kaplan-Meier method and log-rank test were utilized to estimate cumulative OS and PFS. Additionally, uni-and multi-variate Cox regression models were employed to identify signi cant independent factors. ResultsThe median follow-up period in this study was set to be 20.8 months. Following PSM, the one-, two-and three-year cumulative OS rates in the HAIC-Len and HAIC groups were 63.6%, 12.1%, and 3.0%, and 47.2%, 11.8%, and 2.7%, respectively, with a signi cant difference (P < 0.001). The rst-three-year cumulative incidence rates PFS in the HAIC-Len and the HAIC groups were 15.2%, 1.5%, and ND, and 11.8%, 4.5%, and 3.6%, respectively, with no signi cant difference detected(P = 0.092). BMI (HR: 0.709. 95% CI: 0.549, 0.915. P = 0.008) and AST(HR: 1.005. 95% CI: 1.003, 1.007. P < 0.001) represented independent prognostic factors for OS. Additionally, the two groups exhibited no signi cant difference in the incidence rates of adverse events. ConclusionsHAIC-Len signi cantly improved survival outcomes of patients with Ad-HCC and demonstrated acceptable toxicity compared to HAIC alone.

Objective To investigate efficacy and safety of hepatic arterial infusion chemotherapy combined with lenvatinib(HAIC-Len) and HAIC alone for the treatment of advanced hepatocellular carcinoma(Ad-HCC). Methods Totally 349 patients with Ad-HCC participated in the research from February 2018 to October 2020. On the basis of propensity score matching(PSM), 132 and 110 cases were assigned to the HAIC group and the HAIC-Len group, respectively, with a ratio of 1:1. Progression-free survival(PFS), overall survival(OS), and complications were compared between two groups. The Kaplan-Meier method and log-rank test were utilized to estimate cumulative OS and PFS. Additionally, uni- and multi-variate Cox regression models were employed to identify significant independent factors. Results The median follow-up period in this study was set to be 20.8 months. Following PSM, the one-, two- and three-year cumulative OS rates in the HAIC-Len and HAIC groups were 63.6%, 12.1%, and 3.0%, and 47.2%, 11.8%, and 2.7%, respectively, with a significant difference (P < 0.001). The first-three-year cumulative incidence rates PFS in the HAIC-Len and the HAIC groups were 15.2%, 1.5%, and ND, and 11.8%, 4.5%, and 3.6%, respectively, with no significant difference detected(P = 0.092). BMI (HR: 0.709. 95% CI: 0.549, 0.915. P = 0.008) and AST(HR: 1.005. 95% CI: 1.003, 1.007. P < 0.001) represented independent prognostic factors for OS. Additionally, the two groups exhibited no significant difference in the incidence rates of adverse events. Conclusions HAIC-Len significantly improved survival outcomes of patients with Ad-HCC and demonstrated acceptable toxicity compared to HAIC alone.